Texas Oncology Northeast Texas

Clinical research site in Tyler, Texas · 910 E HOUSTON ST, SUITE 100, TYLER, TX 75702-8369 · (903) 579-9800

Part of US Oncology

As of July 2026, 38 paid clinical trials are recruiting at Texas Oncology Northeast Texas in Tyler, Texas. Active studies at this site cover conditions such as Carcinoma, Non-Small-Cell Lung, Advanced Non-Small Cell Lung Cancer and Carcinoma, Non-Small-Cell Lung (NSCLC). Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Texas Oncology Northeast Texas (38)

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

for Non-small Cell Lung Cancer (NSCLC)

37 locations incl. Daphne

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07361497·Phase 3·Recruiting·Listed Jan 2026

Apply to this trial

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

for Advanced Non-Small Cell Lung Cancer

186 locations incl. Bullhead City

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07222566·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

for Intestinal Neoplasms

166 locations incl. Chandler

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07222800·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

29 locations incl. Birmingham

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07266441·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

for Metastatic Castration-resistant Prostate Cancer

34 locations incl. Goodyear

Sponsor: Amgen

Sex: Male·Age: 18+

Code: NCT07213674·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

for Non-small Cell Carcinoma

133 locations incl. Alabaster

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07144280·Phase 3·Recruiting·Listed Aug 2025

Apply to this trial

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

for Breast Cancer

102 locations incl. Chandler

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07062965·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

for Carcinoma, Non-Small-Cell Lung

129 locations incl. Daphne

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06667076·Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

for Small-cell Lung Cancer

50 locations incl. Casa Grande

Sponsor: Amgen

Sex: All·Age: 18 - 99

Code: NCT07005128·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

for Ovarian Cancer

24 locations incl. La Jolla

Sponsor: AbbVie

Sex: Female·Age: 18+

Code: NCT07059845·Phase 2·Recruiting·Listed Jul 2025

Apply to this trial

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

for Breast Cancer

134 locations incl. Daphne

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT06966453·Phase 1, Phase 2·Recruiting·Listed May 2025

Apply to this trial

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

for B-Cell Non-Hodgkins Lymphoma

33 locations incl. Anchorage

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06806033·Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

for Endometrial Cancer

43 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: Female·Age: 18+

Code: NCT06952504·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

for Chronic Lymphocytic Leukemia

43 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06136559·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

for Non-Small Cell Lung Cancer

38 locations incl. Chandler

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT06568939·Phase 2·Recruiting·Listed Aug 2024

Apply to this trial

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

for Carcinoma, Non-Small-Cell Lung

51 locations incl. Birmingham

Sponsor: Mirati Therapeutics Inc.

Sex: All·Age: 18+

Code: NCT06875310·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

36 locations incl. Birmingham

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT06158841·Phase 3·Recruiting·Listed Dec 2023

Apply to this trial

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

for Leukemia, Myeloid, Acute

51 locations incl. Birmingham

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06852222·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

27 locations incl. Phoenix

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT05650632·Phase 1·Recruiting·Listed Dec 2022

Apply to this trial

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

for Epithelial Ovarian Cancer

65 locations incl. Birmingham

Sponsor: AbbVie

Sex: Female·Age: 18+

Code: NCT06890338·Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

for Follicular Lymphoma

31 locations incl. Birmingham

Sponsor: Celgene

Sex: All·Age: 18+

Code: NCT06911502·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

for Small Cell Lung Cancer

30 locations incl. Springdale

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06203210·Phase 3·Recruiting·Listed Jan 2024

Apply to this trial

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

for Mesothelioma

22 locations incl. Phoenix

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT05245500·Phase 1·Recruiting·Listed Feb 2022

Apply to this trial

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

for Urothelial Cancer

11 locations incl. Santa Barbara

Sponsor: Astellas Pharma Global Development, Inc.

Sex: All·Age: 18+

Code: NCT07566156·Phase 3·Recruiting·Listed May 2026

Apply to this trial

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

for Cervical Cancer

18 locations incl. Miami Beach

Sponsor: Merck Sharp & Dohme LLC

Sex: Female·Age: 18+

Code: NCT07216703·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

for Multiple Myeloma

17 locations incl. Scottsdale

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT07095452·Phase 2, Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

for Extensive-Stage Small Cell Lung Cancer

18 locations incl. Daphne

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT06646276·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

for Gastric Cancer

15 locations incl. New Haven

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06731478·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

for Advanced Lung Cancer

16 locations incl. Phoenix

Sponsor: BioNTech SE

Sex: All·Age: 18+

Code: NCT06892548·Phase 1, Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

for Small Cell Lung Cancer Extensive Stage

16 locations incl. Lone Tree

Sponsor: Genprex, Inc.

Sex: All·Age: 18+

Code: NCT05703971·Phase 1, Phase 2·Recruiting·Listed Jan 2023

Apply to this trial

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

for Solid Tumor

20 locations incl. Birmingham

Sponsor: Corbus Pharmaceuticals Inc.

Sex: All·Age: 18+

Code: NCT06603844·Phase 1, Phase 2·Recruiting·Listed Sep 2024

Apply to this trial

A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

for Metastatic Pancreatic Ductal Adenocarcinoma

4 locations incl. Zion

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT07490301·Phase 2, Phase 3·Recruiting·Listed Mar 2026

Apply to this trial

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

for Metastatic Castration-resistant Prostate Cancer

9 locations incl. Aurora

Sponsor: BioNTech SE

Sex: Male·Age: 18+

Code: NCT07365995·Phase 3·Recruiting·Listed Jan 2026

Apply to this trial

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

for Lung Neoplasm Malignant

8 locations incl. Daphne

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06788912·Phase 2·Recruiting·Listed Jan 2025

Apply to this trial

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

for Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

6 locations incl. Morristown

Sponsor: Stingray Therapeutics

Sex: All·Age: 18+

Code: NCT06589440·Phase 2·Recruiting·Listed Sep 2024

Apply to this trial

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)

for Colon Cancer

14 locations incl. Denver

Sponsor: SCRI Development Innovations, LLC

Sex: All·Age: 18+

Code: NCT07011576·Phase 2·Recruiting·Listed Jun 2025

Apply to this trial

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

for Multiple Myeloma

16 locations incl. Tucson

Sponsor: SCRI Development Innovations, LLC

Sex: All·Age: 18+

Code: NCT05972135·Phase 2·Recruiting·Listed Aug 2023

Apply to this trial

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

for Limited-stage Small Cell Lung Cancer (LS-SCLC)

29 locations incl. Goodyear

Sponsor: Shanghai Junshi Bioscience Co., Ltd.

Sex: All·Age: 18+

Code: NCT06095583·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

More research sites in Tyler

Texas Oncology - Northeast Texas (21 trials)
Tyler Research Institute, LLC (14 trials)
Tyler Research Institute (8 trials)
CHRISTUS Trinity Mother Frances Health System (7 trials)
Texas Oncology - Tyler (5 trials)
Texas Oncology (4 trials)
Texas Oncology - Northeast (4 trials)
The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center (4 trials)
Texas Oncology, P.A. - Tyler (3 trials)
Texas Oncology-Northeast Texas (3 trials)

Explore more

Paid clinical trials in Tyler, TX · Texas clinical trials